報價延遲最少15分鐘:2025/05/31 15:56 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
30.98 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.00/-3.48
|
|
企業價值
3.82B
|
| 資產負債 |
|
每股賬面淨值
11.02
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
10.90M
|
|
每股收益
0.08
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/31 15:56 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD. |